Bordeaux, France (June 9, 2021) – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced that it has been chosen to present at the 66th annual ASAIO conference, which will take place on June 10 -12 at the Hilton DC Hotel in Washington, DC.
Laurent Barandon, MD, PhD, Cardiac Surgeon at the University of Bordeaux, FR, and Stephane Garrigue, MD, PhD, Chief Scientific Officer of FineHeart will present In-vivo Assessment of A Novel Ventricular Systole-synchronized, Intraventricular Propelling, Left Ventricular Assist Device For Advanced Heart Failure, selected as one of the top ten cardiac abstracts.
The Presentation will take place on, Thursday, June 10, 2021, at 8:15 am EST (14:15 CET).
The abstract will show the latest preclinical results in terms of performance and mid-term safety…
FineHeart’s technology, ICOMS FLOWMAKER®, is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart’s natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device that is adjustable to patients’ needs, like a pacemaker to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, and lasts on average 90 minutes.
ASAIO’s annual conference globally and collaboratively promotes the development of innovative medical device technology at the crossroads of science, engineering, and medicine. Dedicated sessions are devoted to pediatric and adult mechanical circulatory support, respiratory assist, and VAD coordinator training.
###
ABOUT FINEHEART
FineHeart is a French medical device company headquartered in Bordeaux. Its patented ICOMS innovation holds the potential to treat 200,000 severe heart failure patients annually, with FineHeart initially targeting the 50,000 patients who are eligible for hemodynamic support but today are not treated by current LVADs; a $5B unmet market need.
FineHeart was founded in 2010 by a team of internationally renowned cardiac surgeons and cardiologists, led by Stephane Garrigue, MD, PhD, CSO, Philippe Ritter, MD, MS, co-inventor of cardiac resynchronization therapy (CRT), and FineHeart CEO, Arnaud Mascarell. The company benefits today from 17 patent families.
FineHeart is supported by major U.S. venture capital firms specializing in the cardiovascular space, prime French investors, the European Union, and Region Nouvelle Aquitaine, and Region Centre. It has been recognized by FierceMedTech as one of its “Fierce 15,” designating it as one of the most promising private MedTech companies in the industry. www.fineheart.fr
ABOUT ASAIO
ASAIO is the ideal home for visionaries with innovative ideas and young investigators eager to advance their careers. The Annual Conference provides a venue for young investigators and startups to present early-stage research to an international audience receptive to new concepts in each of these fields. The Annual Conference also offers a one-of-a-kind opportunity to present new concepts to a seasoned audience to get real-time clinical, engineering, and regulatory feedback on the viability of novel technology. The society takes pride in having “respect for all ideas” and creating a culture that encourages interdisciplinary, mixing, blending, and out-of-the-box thinking. www.asaio.org
Media Contact
Company Name: FineHeart
Contact Person: Dana Summers
Email: Send Email
Phone: 334-663-4424
Country: United States
Website: www.fineheart.fr